Literature DB >> 23731273

Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis.

Donald S A McLeod1, David S Cooper, Paul W Ladenson, Kenneth B Ain, James D Brierley, Henry G Fein, Bryan R Haugen, Jacqueline Jonklaas, James Magner, Douglas S Ross, Monica C Skarulis, David L Steward, Harry R Maxon, Steven I Sherman.   

Abstract

BACKGROUND: Serum thyrotropin (TSH) concentration and thyroid autoimmunity may be of prognostic importance in differentiated thyroid cancer (DTC). Preoperative serum TSH level has been associated with higher DTC stage in cross-sectional studies; data are contradictory on the significance of thyroid autoimmunity at the time of diagnosis.
OBJECTIVE: We sought to assess whether preoperative serum TSH and perioperative antithyroglobulin antibodies (TgAb) were associated with thyroid cancer stage and outcome in DTC patients followed by the National Thyroid Cancer Treatment Cooperative Study, a large multicenter thyroid cancer registry.
METHODS: Patients registered after 1996 with available preoperative serum TSH (n=617; the TSH cohort) or perioperative TgAb status (n=1770; the TgAb cohort) were analyzed for tumor stage, persistent disease, recurrence, and overall survival (OS; median follow-up, 5.5 years). Parametric tests assessed log-transformed TSH, and categorical variables were tested with chi square. Disease-free survival (DFS) and OS was assessed with Cox models.
RESULTS: Geometric mean serum TSH levels were higher in patients with higher-stage disease (Stage III/IV=1.48 vs. 1.02 mU/L for Stages I/II; p=0.006). The relationship persisted in those aged ≥45 years after adjusting for sex (p=0.01). Gross extrathyroidal extension (p=0.03) and presence of cervical lymph node metastases (p=0.003) were also significantly associated with higher serum TSH. Disease recurrence and all-cause mortality occurred in 37 and 38 TSH cohort patients respectively, which limited the power for survival analysis. Positive TgAb was associated with lower stage on univariate analysis (positive TgAb in 23.4% vs. 17.8% of Stage I/II vs. III/IV patients, respectively; p=0.01), although the relationship lost significance when adjusting for age and sex (p=0.34). Perioperative TgAb was not an independent predictor of DFS (hazard ratio=1.12 [95% confidence interval=0.74-1.69]) or OS (hazard ratio=0.98 [95% confidence interval=0.56-1.72]).
CONCLUSIONS: Preoperative serum TSH level is associated with higher DTC stage, gross extrathyroidal extension, and neck node metastases. Perioperative TgAb is not an independent predictor of DTC prognosis. A larger cohort is required to assess whether preoperative serum TSH level predicts recurrence or mortality.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23731273      PMCID: PMC3887423          DOI: 10.1089/thy.2013.0062

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  35 in total

Review 1.  Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis.

Authors:  Donald S A McLeod; Karen F Watters; Anthony D Carpenter; Paul W Ladenson; David S Cooper; Eric L Ding
Journal:  J Clin Endocrinol Metab       Date:  2012-05-23       Impact factor: 5.958

2.  Radioiodine therapy in patients with stage I differentiated thyroid cancer.

Authors:  Jacqueline Jonklaas; David S Cooper; Kenneth B Ain; Thomas Bigos; James D Brierley; Bryan R Haugen; Paul W Ladenson; James Magner; Douglas S Ross; Monica C Skarulis; David L Steward; Harry R Maxon; Steven I Sherman
Journal:  Thyroid       Date:  2010-11-07       Impact factor: 6.568

Review 3.  A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example.

Authors:  J D Brierley; T Panzarella; R W Tsang; M K Gospodarowicz; B O'Sullivan
Journal:  Cancer       Date:  1997-06-15       Impact factor: 6.860

Review 4.  Autoimmunity in differentiated thyroid cancer: significance and related clinical problems.

Authors:  Ulla Feldt-Rasmussen; Ase Krogh Rasmussen
Journal:  Hormones (Athens)       Date:  2010 Apr-Jun       Impact factor: 2.885

5.  The impact of age and gender on papillary thyroid cancer survival.

Authors:  J Jonklaas; G Nogueras-Gonzalez; M Munsell; D Litofsky; K B Ain; S T Bigos; J D Brierley; D S Cooper; B R Haugen; P W Ladenson; J Magner; J Robbins; D S Ross; M C Skarulis; D L Steward; H R Maxon; S I Sherman
Journal:  J Clin Endocrinol Metab       Date:  2012-04-10       Impact factor: 5.958

6.  Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases.

Authors:  Fulvio Basolo; Liborio Torregrossa; Riccardo Giannini; Mario Miccoli; Cristiana Lupi; Elisa Sensi; Piero Berti; Rossella Elisei; Paolo Vitti; Angelo Baggiani; Paolo Miccoli
Journal:  J Clin Endocrinol Metab       Date:  2010-07-14       Impact factor: 5.958

7.  Staging systems for papillary thyroid carcinoma: a study of 2 tertiary referral centers.

Authors:  Brian Hung-Hin Lang; Sin-Ming Chow; Chung-Yau Lo; Stephen C K Law; King-Yin Lam
Journal:  Ann Surg       Date:  2007-07       Impact factor: 12.969

8.  The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland.

Authors:  S Matsubayashi; K Kawai; Y Matsumoto; T Mukuta; T Morita; K Hirai; F Matsuzuka; K Kakudoh; K Kuma; H Tamai
Journal:  J Clin Endocrinol Metab       Date:  1995-12       Impact factor: 5.958

9.  Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry.

Authors:  D S Cooper; B Specker; M Ho; M Sperling; P W Ladenson; D S Ross; K B Ain; S T Bigos; J D Brierley; B R Haugen; I Klein; J Robbins; S I Sherman; T Taylor; H R Maxon
Journal:  Thyroid       Date:  1998-09       Impact factor: 6.568

10.  Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer.

Authors:  M Saji; K Narahara; S K McCarty; V V Vasko; K M La Perle; K Porter; D Jarjoura; C Lu; S-Y Cheng; M D Ringel
Journal:  Oncogene       Date:  2011-05-02       Impact factor: 9.867

View more
  36 in total

1.  Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012.

Authors:  Aubrey A Carhill; Danielle R Litofsky; Douglas S Ross; Jacqueline Jonklaas; David S Cooper; James D Brierley; Paul W Ladenson; Kenneth B Ain; Henry G Fein; Bryan R Haugen; James Magner; Monica C Skarulis; David L Steward; Mingxhao Xing; Harry R Maxon; Steven I Sherman
Journal:  J Clin Endocrinol Metab       Date:  2015-07-14       Impact factor: 5.958

2.  Vascular endothelial growth factor G+405C polymorphism may contribute to the risk of developing papillary thyroid carcinoma.

Authors:  İlknur Bingül; Pervin Vural; Semra Doğru-Abbasoğlu; Esra Çil; Müjdat Uysal
Journal:  J Clin Lab Anal       Date:  2016-12-07       Impact factor: 2.352

Review 3.  Differentiated thyroid cancer-personalized therapies to prevent overtreatment.

Authors:  Markus Luster; Theresia Weber; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2014-07-01       Impact factor: 43.330

4.  Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies.

Authors:  Cosimo Durante; Sara Tognini; Teresa Montesano; Fabio Orlandi; Massimo Torlontano; Efisio Puxeddu; Marco Attard; Giuseppe Costante; Salvatore Tumino; Domenico Meringolo; Rocco Bruno; Fabiana Trulli; Maria Toteda; Adriano Redler; Giuseppe Ronga; Sebastiano Filetti; Fabio Monzani
Journal:  Thyroid       Date:  2014-05-21       Impact factor: 6.568

Review 5.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

Review 6.  Prognostic biomarkers in thyroid cancer.

Authors:  Paula Soares; Ricardo Celestino; Miguel Melo; Elsa Fonseca; Manuel Sobrinho-Simões
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

7.  Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion.

Authors:  Alyaksandr V Nikitski; Susan L Rominski; Mamta Wankhede; Lindsey M Kelly; Federica Panebianco; Guillermo Barila; Daniel L Altschuler; Yuri E Nikiforov
Journal:  Am J Pathol       Date:  2018-08-18       Impact factor: 4.307

Review 8.  New insights in risk stratification of differentiated thyroid cancer.

Authors:  Maria Papaleontiou; Megan R Haymart
Journal:  Curr Opin Oncol       Date:  2014-01       Impact factor: 3.645

9.  Association between preoperative thyrotrophin and clinicopathological and aggressive features of papillary thyroid cancer.

Authors:  Abbas Ali Tam; Didem Ozdemir; Cevdet Aydın; Nagihan Bestepe; Serap Ulusoy; Nuran Sungu; Reyhan Ersoy; Bekir Cakir
Journal:  Endocrine       Date:  2018-01-27       Impact factor: 3.633

10.  A pilot study of serum selenium, vitamin D, and thyrotropin concentrations in patients with thyroid cancer.

Authors:  Jacqueline Jonklaas; Mark Danielsen; Hong Wang
Journal:  Thyroid       Date:  2013-07-17       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.